APA (7th ed.) Citation

Yang H, Sun S, Mei Z, Xiang Q, Yang C, Chen M, . . . Qiu H. (2021). A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy. Dove Medical Press.

Chicago Style (17th ed.) Citation

Yang H, Sun S, Mei Z, Xiang Q, Yang C, Chen M, Xie C, Zhou Y, and Qiu H. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy. Dove Medical Press, 2021.

MLA (9th ed.) Citation

Yang H, et al. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy. Dove Medical Press, 2021.